Not Yet RecruitingNot Applicable

Sympathetic Ablation for Ventricular Arrhythmias

10 participantsStarted 2026-04

Plain-language summary

Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18 or older at the time of informed consent
✓. Willing and capable of providing written informed consent
✓. Implanted ICD or CRT-D
✓. Recurrent VT leading to ICD therapy (ATP or shock)
✓. Indicated for catheter ablation of VT per international guidelines
✓. No prior instrumentation or resection of the stellate ganglia, or surgical procedure that may have disturbed the stellate ganglia

Exclusion criteria

✕. Contraindication to percutaneous femoral arterial access
✕. Heparin-induced thrombotic thrombocytopenia
✕. Prior surgical sympathectomy
✕. ECMO therapy in the past 30 days
✕. Contraindicated for advanced heart failure therapies (LVAD or heart transplantation)
✕. A most recently documented LVEF \<20% in the past 30 days
✕. Receiving inotropic drug therapy
✕. Women of childbearing potential who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test at enrollment

What they're measuring

Freedom from device and procedure-related serious adverse events (SAEs)

Timeframe: 3 months

VT burden (episodes per month)

Timeframe: 3 months

Trial details

NCT IDNCT07501819

SponsorSymKardia

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Imad Libbus, PhD

651-242-4431 imad.libbus@symkardia.com

View on ClinicalTrials.gov More Ventricular Tachycardia (VT) trials